APOE type (Alzheimer's & cholesterol)

APOE comes in three versions, e2, e3 and e4, and your pair of them shifts both late-onset Alzheimer's risk and blood cholesterol. The two markers this reads mean nothing on their own; only the combination names your type, so they must be read together.

Why two markers define three versions

APOE comes in three common forms, e2, e3 and e4, and they are defined by the combination of two positions in the gene rather than by any single one. That is why neither marker means anything alone and both must be read together: it is the pairing that names your type, and you have two copies, one from each parent.

The protein itself carries cholesterol in the blood and, in the brain, moves lipids between cells and takes part in clearing amyloid beta. The three versions differ in how well they do this, which is the shared root of the cholesterol and the Alzheimer's associations.

How large the Alzheimer's association is

APOE is the largest common genetic risk factor for late-onset Alzheimer's disease by a wide margin. In meta-analysis of non-Hispanic white populations, one e4 copy carries roughly 3 times the odds and two copies around 15 times, against the common e3/e3 pairing. The e2 form is protective in the opposite direction.

Those are relative figures on a condition whose absolute risk is dominated by age. Many people with two e4 copies never develop Alzheimer's disease, and most people who do develop it are not e4 homozygotes.

The risk differs substantially by ancestry

This is one of the clearest ancestry effects in common disease genetics, and it runs in both directions. Reported odds for one e4 copy range from about 3.1 to 5.6 in East Asian populations and about 3.2 in non-Hispanic white populations, but only about 1.1 to 2.2 in African-ancestry and Hispanic populations. For two copies the spread is wider still, from around 2.2 to 5.7 in African-ancestry samples up to 11.8 to 33.1 in East Asian ones.

The variant is the same everywhere; what differs is the genetic background it sits on. A single number for e4 risk is therefore wrong for most of the world, and any tool that reports one should be read with that in mind.

What APOE does to cholesterol

The lipid side is less discussed and more immediately actionable. The e4 form is associated with higher LDL cholesterol and the e2 form with lower, and this is measurable in a standard blood test rather than inferred.

The one pairing that carries a specific medical footnote is e2/e2, which is the genetic background for type III hyperlipoproteinemia, an uncommon lipid disorder. Most people with e2/e2 never develop it, but it is a reason to have cholesterol and triglycerides checked at some point.

Why this result deserves a moment's thought before reading

There is no treatment that changes the course of late-onset Alzheimer's disease on the basis of an APOE result, and the American College of Medical Genetics is explicit that genetic risk information of this kind is a statistical prediction rather than a diagnosis. Some people find it useful for planning and others find it distressing without being actionable, which is why genetic counselling exists for exactly this result.

One clinical detail has emerged recently and is worth knowing if it ever becomes relevant: in trials of the anti-amyloid antibodies lecanemab and donanemab, e4 carriers had higher rates of amyloid-related imaging abnormalities, brain swelling and small bleeds, with roughly twice the rate of the swelling type and around three times the rate of the microbleed type compared with non-carriers, and homozygotes highest of all. APOE status is now part of that treatment discussion.

What this result does not cover

Early-onset autosomal dominant Alzheimer's disease, caused by variants in APP, PSEN1 or PSEN2, is a different condition and is not read here. Dementia appearing in a family before 60 across generations is a reason for clinical genetics input rather than an APOE result.

A rare e1 form exists and cannot be resolved from these two markers, and neither can the exact pairing when both an e2 and an e4 signal are present. The score also says nothing about the many other genes now known to affect Alzheimer's risk in smaller amounts.

What each APOE result means

APOE e2/e2, lowest Alzheimer's risk (lipid caveat). You carry two e2 copies, the lowest genetic Alzheimer's risk and generally lower LDL cholesterol. The one thing to know is that e2/e2 is the genetic background for a rare lipid disorder (type III hyperlipoproteinemia), so it's worth having cholesterol and triglycerides checked with your doctor at some point.

APOE e2/e3, lower Alzheimer's risk. You carry one protective e2 copy, associated with somewhat lower genetic risk of late-onset Alzheimer's (around 0.6 times average) and modestly lower heart-disease risk. That's favorable, though it doesn't remove risk, since age, lifestyle and other genes still matter.

APOE e3/e3, average Alzheimer's risk. You carry the most common pair, e3/e3, the baseline for both Alzheimer's risk and cholesterol, so your APOE-related risk is neither raised nor lowered. Average is not zero, so the usual brain- and heart-healthy habits still apply.

APOE e2/e4, mixed, moderately higher risk. You carry one protective e2 and one risk e4, which nets out to a moderately increased Alzheimer's risk (around 2 to 3 times average). One caveat: this exact result cannot be fully resolved from this kind of test and is read as e2/e4 by the usual convention. A risk factor is not a diagnosis.

APOE e3/e4, higher Alzheimer's risk. You carry one e4 copy, which is associated with roughly 2 to 3 times the average genetic risk of late-onset Alzheimer's and a slightly higher cholesterol profile. This is a risk factor, not a diagnosis, and many people with this genotype never develop Alzheimer's. Brain- and heart-healthy habits are the practical takeaway.

APOE e4/e4, highest Alzheimer's risk. You carry two e4 copies, the strongest genetic association with late-onset Alzheimer's (studies in European-ancestry groups suggest roughly 10 to 15 times the average risk, and the effect varies by ancestry) along with higher LDL cholesterol. This is still a risk factor and not a certainty: many e4/e4 people never develop Alzheimer's. Because the implications are significant, genetic counseling is strongly worth considering.

APOE rare type, interpret with care. Your two markers fall into a rare combination that points to the uncommon e1 form, which this kind of test cannot pin down cleanly. The standard e2/e3/e4 interpretation doesn't apply confidently here, so treat this as inconclusive and consider a dedicated test or genetic counseling if APOE matters to you.

Evidence & sources

This panel reads APOE e4 (rs429358) and APOE e2 (rs7412).

These two markers fully define the standard APOE e2/e3/e4 type, so this is a complete read of the gene's common variants, not a stand-in. A rare e1 form and the exact pairing of e2 with e4 cannot be worked out from this kind of test.

Common questions

I have one e4 copy. What does that actually mean? In non-Hispanic white populations it corresponds to roughly 3 times the odds of late-onset Alzheimer's disease compared with the common e3/e3 pairing, and the figure is lower in African-ancestry and Hispanic populations and higher in East Asian ones. Age remains the dominant factor, and most e4 carriers do not develop the disease.

Can I do anything about an e4 result? Nothing that depends on the genotype. What has evidence for brain health applies to everyone: blood pressure control, physical activity, not smoking, treating hearing loss, sleep and staying socially and mentally engaged. If the result is troubling, genetic counselling is a reasonable route.

Does APOE affect my cholesterol? Yes, and that part is measurable. The e4 form associates with higher LDL and e2 with lower. The e2/e2 pairing is also the background for a rare lipid disorder, type III hyperlipoproteinemia, which is worth a cholesterol and triglyceride check.

Related

Factor V Leiden thrombophilia · Fasting glucose / type 2 diabetes (MTNR1B) · HbA1c (blood sugar) · Longevity-associated variant (FOXO3) · Prothrombin clotting variant · Type 2 diabetes risk · Uric acid / gout tendency